Neurobehavioral Treatment Discovery Team

Publications

Mckinney, WS; Nelson, M; Shaffer, RC; Dominick, KC; Erickson, CA; Schmitt, LM. Brief Report: Differences Between Stanford-Binet Abbreviated and Full-Scale Estimates of IQ in Fragile X Syndrome Vary Across Development. Journal of Autism and Developmental Disorders. 2025.

Kaufmann, WE; Horn, PS; Budimirovic, DB; Harris, HK; Lozano, R. Relationship Between Intellectual Disability and Behavioral Comorbidity in Children With Fragile X Syndrome. Journal of Autism and Developmental Disorders. 2025.

Chang, X; Li, W; Matsui, S; Huynh, C; Erickson, C; Guo, F; Cederquist, GY; Studer, L; Iwafuchi, M; Shillington, A; Chronis, C; Tchieu, J. ZMYND11 functions in bimodal regulation of latent genes and brain-like splicing to safeguard corticogenesis. Nature Communications. 2025; 16(1):9010.

Magnusen, AF; Hopkin, RJ; Vorhees, C; Wilson, E; Moehlman, M; Hallinan, B; Erickson, C; Delbello, MP; Marsili, L; Coufal, NG; Pandey, MK. Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder. Brain, Behavior, & Immunity - Health. 2025; 48:101091.

Elmaghraby, R; Liu, Y; Ramesh, P; Westerkamp, G; Nelson, MA; Larsh, T; Smith, E; Gilbert, DL; Wu, SW; Erickson, CA; Pedapati, EV. Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome. Molecular Autism. 2025; 16(1):49.

Padma, MPSRK; Elmaghraby, R; Pedapati, E; Blank, EJ; Erickson, CA. Cognitive Flexibility in Autism: New Tools for Understanding and Treatment. Journal of the American Academy of Child and Adolescent Psychiatry. 2025; 64(10):s335.

Erickson, CA; Shaffer, RC; Will, M; Schmitt, LM; Horn, P; Hirst, K; Pedapati, EV; Ober, N; Tumuluru, RV; Handen, BL; Beversdorf, DQ. Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2025; 55(9):3387-3394.

Oberman, LM; Berry-Kravis, E; Budimirovic, DB; Erickson, CA; Hagerman, RJ; Harris, HK; Hessl, D; Lozano, R; Thurm, A; Tartaglia, N; Tran, J; Kaufmann, WE. The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity. Journal of Child and Adolescent Psychopharmacology. 2025; 35(7):399-415.

Henneberry, EA; Erickson, CA. Alpha-2 Agonists in Autism Spectrum Disorder. In: Lifespan Treatment for Autistic Individuals. Oxford University Press (OUP); 2025:607-620.

Miyakoshi, M; Kim, H; De Stefano, LA; Schmitt, LM; Norris, JE; Ethridge, LE; Erickson, CA; Pedapati, EV. Hyper-extralemniscal model of Fragile X syndrome. Cerebral Cortex. 2025; 35(6).

Argonis, RA; Pedapati, EV; Dominick, KC; Harris, K; Lamy, M; Fosdick, C; Schmitt, L; Shaffer, RC; Smith, E; Will, M; Mcdougle, CJ; Erickson, CA. Patterns in Medication Use for Treatment of Depression in Autistic Spectrum Disorder. Journal of Autism and Developmental Disorders. 2025; 55(6):1969-1975.

Nelson, MA; Shaffer, RC; Schmitt, LM; Coffman, MC; Horn, PS; Reisinger, DL; Erickson, CA. Health Related Quality of Life in Autistic Youth and Their Families. Journal of Autism and Developmental Disorders. 2025; 55(6):1982-1987.

Mckinney, WS; Schmitt, LM; De Stefano, LA; Ethridge, L; Norris, JE; Horn, PS; Dauterman, S; Rosselot, H; Pedapati, EV; Reisinger, DL; Friedman, NR; Hong, M; Sweeney, JA; Erickson, C. Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome. Journal of Child and Adolescent Psychopharmacology. 2025; 35(4):211-221.

Elmaghraby, R; Blank, E; Miyakoshi, M; Gilbert, DL; Wu, SW; Larsh, T; Westerkamp, G; Liu, Y; Horn, PS; Erickson, CA; Pedapati, EV. Probing the Neurodynamic Mechanisms of Cognitive Flexibility in Depressed Individuals with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology. 2025; 35(4):231-243.

Blank, E; Gilbert, DL; Wu, SW; Larsh, T; Elmaghraby, R; Liu, R; Smith, E; Westerkamp, G; Liu, Y; Horn, PS; Greenstein, E; Sweeney, JA; Erickson, CA; Pedapati, EV. Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2025; 55(3):940-954.

Zappia, KJ; Erickson, CA. Psychopharmacology in Autism. In: Handbook of Evidence-Based Practices in Autism Spectrum Disorder. Springer Nature; 2025:315-340.

Edwards, R; Murphy, G; Owens, JW; Erickson, C; Hopkin, R; Shillington, A. Dual Diagnosis of Fragile X Syndrome and DEPDC5-Related Disorder Emphasizes DEPDC5's Role Beyond Familial Epilepsy: A Case Report and Literature Review. Case Reports in Genetics. 2025; 2025:4501466.

Pedapati, EV; Ethridge, LE; Liu, Y; Liu, R; Sweeney, JA; Destefano, LA; Miyakoshi, M; Razak, K; Schmitt, LM; Moore, DR; Dominick, KC; Horn, PS; Binder, D; Erickson, CA. Frontal cortex hyperactivation and gamma desynchrony in Fragile X syndrome: Correlates of auditory hypersensitivity. PLoS ONE. 2025; 20(5):e0306157.

Zappia, KJ; Erickson, CA. Psychopharmacology in Autism. In: Handbook of Evidence Based Practices in Autism Spectrum Disorder. 2025:315-340.

Citarella, J; Siekierski, P; Ethridge, L; Westerkamp, G; Liu, Y; Blank, E; Voorhees, L; Batterink, L; Jones, SR; Smith, E; Horn, PS; De Stefano, LA; Erickson, CA; Pedapati, EV. FX ENTRAIN: scientific context, study design, and biomarker driven brain-computer interfaces in neurodevelopmental conditions. Frontiers in Neuroscience. 2025; 19:1618804.

Mckinney, WS; Corsmeier, A; Dapore, A; Gross, C; Dominick, KC; Erickson, CA; Schmitt, LM. Beyond the Fragile X protein: neighborhood characteristics explain individual differences in IQ and adaptive behaviors of Fragile X syndrome. Frontiers in Psychiatry. 2025; 16:1636987.

Smith, E; Dominick, KC; Schmitt, LM; Pedapati, EV; Erickson, CA. Specialization of the brain for language in children with Fragile X Syndrome: a functional Near Infrared Spectroscopy study. Journal of Neurodevelopmental Disorders. 2024; 16(1):69.

Ammerman, RT; Erickson, CA. Innovative Approaches to Addressing Pediatric Mental Health. Pediatric Clinics of North America. 2024; 71(6):xvii-xix.

Nelson, MA; Schmitt, LM; Horn, PS; Berry-Kravis, E; Hessl, D; Shaffer, RC; Carpenter, R; Budimirovic, DB; Wang, P; Reisinger, DL; Walton-Bowen, K; Erickson, CA. Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds. Journal of Autism and Developmental Disorders. 2024.

Schmitt, LM; Nelson, M; Shaffer, RC; Erickson, CA. A near normal distribution of IQ in Fragile X Syndrome. Scientific Reports. 2024; 14(1):23058.

Ethridge, LE; Pedapati, EV; Schmitt, LM; Norris, JE; Auger, E; De Stefano, LA; Sweeney, JA; Erickson, CA. Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome. Scientific Reports. 2024; 14(1):22982.

Wright, JR; Astrovskaya, I; Barns, SD; Goler, A; Zhou, X; Shu, C; Snyder, LG; Han, B; Shen, Y; Volfovsky, N; Hall, JB; Feliciano, P; Chung, WK. Return of genetic research results in 21,532 individuals with autism. Genetics in Medicine. 2024; 26(10):101202.

Erickson, CA; Perez-Cano, L; Pedapati, EV; Painbeni, E; Bonfils, G; Schmitt, LM; Sachs, H; Nelson, M; De Stefano, L; Westerkamp, G; Issachar, G; Blaettler, T; Hyvelin, J-M; Durham, LA. Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 2024; 12(7).

Sadhwani, A; Powers, S; Wheeler, A; Miller, H; Potter, SN; Peters, SU; Bacino, CA; Skinner, SA; Wink, LK; Erickson, CA; Bird, LM; Tan, W-H. Developmental milestones and daily living skills in individuals with Angelman syndrome. Journal of Neurodevelopmental Disorders. 2024; 16(1):32.

Simpson, S; Dominick, KC; Erickson, CA; Lamy, M. Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. Journal of Autism and Developmental Disorders. 2024.

Elsayed, Z; Suer, N; Westerkamp, G; Liu, JY; Miyakoshi, M; Erickson, C; Pedapati, E. CNN Brain Label-Maker: Computer Vision Based ICA Rejection EEG based System Architecture. The International FLAIRS Conference Proceedings. 2024; 37.

Takarae, Y; Zanesco, A; Erickson, CA; Pedapati, EV. EEG Microstates as Markers for Cognitive Impairments in Fragile X Syndrome. Brain Topography. 2024; 37(3):432-446.

Zappia, KJ; Shillington, A; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. Neurodevelopmental Disorders Including Autism Spectrum Disorder and Intellectual Disability as a Risk Factor for Delayed Diagnosis of Catatonia. Journal of Developmental and Behavioral Pediatrics. 2024; 45(2):e137-e142.

Kaufmann, WE; Raspa, M; Bann, CM; Gable, JM; Harris, HK; Budimirovic, DB; Lozano, R. Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome. Journal of Autism and Developmental Disorders. 2024; 54(2):725-737.

Protic, D; Breeze, E; Mendoza, G; Zafarullah, M; Abbeduto, L; Hagerman, R; Coffey, C; Cudkowicz, M; Durbin-Johnson, B; Ashwood, P; Talboy, A; Tartaglia, N; Veenstra-Vanderweele, J; Tassone, F. Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. SAGE Open Medicine. 2024; 12:20503121241282401.

Pascarella, L; Erickson, C; Minshawi, NF. From Kanner to DSM-V. In: Handbook of Early Intervention for Autism Spectrum Disorders. Springer Nature; 2024:15-32.

Berry-Kravis, E; Erickson, C. Fragile X Syndrome. In: Neuropsychiatric Care for Genetic Syndromes and Other Neurodevelopmental Disorders. Springer Nature; 2024:109-127.

Liu, R; Pedapati, EV; Schmitt, LM; Shaffer, RC; Smith, EG; Dominick, KC; Destefano, LA; Westerkamp, G; Horn, P; Sweeney, JA; Erickson, CA. Reliability of resting-state electrophysiology in fragile X syndrome. Biomarkers in Neuropsychiatry. 2023; 9.

Rahmatullah, N; Schmitt, LM; De Stefano, L; Post, S; Robledo, J; Chaudhari, G; Pedapati, E; Erickson, C; Portera-Cailliau, C; Goel, A. Hypersensitivity to Distractors in Fragile X Syndrome from Loss of Modulation of Cortical VIP Interneurons. Journal of Neuroscience. 2023; 43(48):8172-8188.

Shillington, A; Zappia, KJ; White, L; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. Genetic syndromes are prevalent in patients with comorbid neurodevelopmental disorders and catatonia. American Journal of Medical Genetics, Part A. 2023; 191(11):2716-2722.

Berry-Kravis, E; Abbeduto, L; Hagerman, R; Coffey, CS; Cudkowicz, M; Erickson, CA; Mcduffie, A; Hessl, D; Ethridge, L; Tassone, F; Ecklund, D; Costigan, M; Huff, T; Pearson, B. Effects of AFQ056 on language learning in fragile X syndrome. Journal of Clinical Investigation. 2023; 134(5).

Kang, S; Jones, A; Shaffer, RC; Erickson, CA; Schmitt, LM. Developing improved outcome measures in FXS: Key stakeholder feedback. Research in Developmental Disabilities. 2023; 137:104502.

Erickson, CA; Tessier, CR; Gross, C; Pedapati, EV; Wink, LK; Dominick, KC; Shaffer, RC; Rosselot, H; Hong, MP; Bantel, AP; Berry-Kravis, E; Horn, PS; Adams, R; Sweeney, JA. Lymphocytic Extracellular Signal-Regulated Kinase Dysregulation in Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2023; 62(5):582-592.e2.

Shaffer, RC; Schmitt, LM; Reisinger, DL; Coffman, M; Horn, P; Goodwin, MS; Mazefsky, C; Randall, S; Erickson, C. Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers. Journal of Autism and Developmental Disorders. 2023; 53(5):1942-1962.

Schmitt, LM; Smith, EG; Pedapati, EV; Horn, PS; Will, M; Lamy, M; Barber, L; Trebley, J; Meyer, K; Heiman, M; West, KHJ; Hughes, P; Ahuja, S; Erickson, CA. Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. Scientific Reports. 2023; 13(1):5192.

Straub, D; Schmitt, LM; Boggs, AE; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Scientific Reports. 2023; 13(1):3808.

Jones, A; Kang, S; Shaffer, RC; Erickson, CA; Schmitt, LM. Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates. Frontiers in Psychology. 2023; 14:1118652.

Norris, JE; Schmitt, LM; De Stefano, LA; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience. 2023; 17:898215.

Schmitt, LM; Li, J; Liu, R; Horn, PS; Sweeney, JA; Erickson, CA; Pedapati, EV. Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular Autism. 2022; 13(1):47.

Norris, JE; Destefano, LA; Schmitt, LM; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS Chemical Neuroscience. 2022; 13(23):3389-3402.

Rosen, V; Blank, E; Lampert, E; Dominick, K; Will, M; Erickson, C; Pedapati, E; Lamy, M; Shaffer, R. Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19. Journal of Autism and Developmental Disorders. 2022; 52(12):5253-5265.

Berry-Kravis, E; Hagerman, R; Budimirovic, D; Erickson, C; Heussler, H; Tartaglia, N; Cohen, J; Tassone, F; Dobbins, T; Merikle, E; Sebree, T; Tich, N; Palumbo, JM; O'quinn, S. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders. 2022; 14(1):56.

Pedapati, E; Ethridge, L; Sweeney, J; Miyakoshi, M; Schmitt, L; Liu, R; Wu, S; Gilbert, D; Horn, P; Erickson, CA. THALAMOCORTICAL DYSRHYTHMIA AS A UNIFYING MODEL OF NEUROPSYCHIATRIC AND NEUROSENSORY DYSFUNCTION IN FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61(10):s275-s276.

Jonak, CR; Pedapati, EV; Schmitt, LM; Assad, SA; Sandhu, MS; Destefano, L; Ethridge, L; Razak, KA; Sweeney, JA; Binder, DK; Erickson, CA. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2022; 14(1):52.

Lozano, R; Thompson, T; Dixon-Weber, J; Erickson, CA; Berry-Kravis, E; Williams, S; Smith, E; Frazier, JA; Rosselot, H; Farmer, C; Hessl, D. Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives. Genes. 2022; 13(9).

Schmitt, LM; Sweeney, JA; Erickson, CA; Shaffer, R. Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2022; 52(9):4191-4199.

Zhou, X; Feliciano, P; Shu, C; Wang, T; Astrovskaya, I; Hall, JB; Obiajulu, JU; Wright, JR; Murali, SC; Xu, SX; Volfovsky, N; Eichler, EE; Shen, Y; Chung, WK. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nature Genetics. 2022; 54(9):1305-1319.

Holley, AJ; Shedd, A; Boggs, A; Lovelace, J; Erickson, C; Gross, C; Jankovic, M; Razak, K; Huber, K; Gibson, JR. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons. Neurobiology of Disease. 2022; 170:105767.

Albizua, I; Charen, K; Shubeck, L; Talboy, A; Berry-Kravis, E; Kaufmann, WE; Stallworth, JL; Drazba, KT; Erickson, CA; Sweeney, JA; Sherman, SL; Warren, ST; Jin, P; Allen, EG. Descriptive analysis of seizures and comorbidities associated with fragile X syndrome. Molecular Genetics & Genomic Medicine. 2022; 10(8):e2001.

Yurkovic-Harding, J; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Yu, C; Kennedy, DP. Children with ASD establish joint attention during free-flowing toy play without face looks. Current Biology. 2022; 32(12):2739-2746.e4.

Pedapati, EV; Schmitt, LM; Ethridge, LE; Miyakoshi, M; Sweeney, JA; Liu, R; Smith, E; Shaffer, RC; Dominick, KC; Gilbert, DL; Binder, DK; Lamy, M; Axford, M; Erickson, CA. Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Communications Biology. 2022; 5(1):442.

Mcdougle, CJ; Thom, RP; Ravichandran, CT; Palumbo, ML; Politte, LC; Mullett, JE; Keary, CJ; Erickson, CA; Stigler, KA; Mathieu-Frasier, L; Posey, DJ. A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology. 2022; 47(6):1263-1270.

Boggs, AE; Schmitt, LM; Mclane, RD; Adayev, T; Lafauci, G; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Scientific Reports. 2022; 12(1):5617.

Beversdorf, DQ; Anagnostou, E; Hardan, A; Wang, P; Erickson, CA; Frazier, TW; Veenstra-Vanderweele, J. Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Frontiers in Psychiatry. 2022; 13:1079006.

Schmitt, LM; Arzuaga, AL; Dapore, A; Duncan, J; Patel, M; Larson, JR; Erickson, CA; Sweeney, JA; Ragozzino, ME. Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Frontiers in Behavioral Neuroscience. 2022; 16:1074682.

Shillington, A; Lamy, M; Dominick, KC; Sorter, M; Erickson, CA; Hopkin, R. A Collaborative Psychiatric-Genetics Inpatient Care Delivery Model Improves Access to Clinical Genetic Evaluation, Testing, and Diagnosis for Patients With Neurodevelopmental Disorders. Frontiers in Genetics. 2022; 13:901458.

Shu, C; Green Snyder, L; Shen, Y; Chung, WK. Imputing cognitive impairment in SPARK, a large autism cohort. Autism Research. 2022; 15(1):156-170.

Henneberry, E; Lamy, M; Dominick, KC; Erickson, CA. Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2021; 51(12):4370-4394.

Dominick, KC; Andrews, HF; Kaufmann, WE; Berry-Kravis, E; Erickson, CA. Psychotropic Drug Treatment Patterns in Persons with Fragile X Syndrome. Journal of Child and Adolescent Psychopharmacology. 2021; 31(10):659-669.

White, LC; Law, JK; Daniels, AM; Toroney, J; Vernoia, B; Xiao, S; Feliciano, P; Chung, WK. Brief Report: Impact of COVID-19 on Individuals with ASD and Their Caregivers: A Perspective from the SPARK Cohort. Journal of Autism and Developmental Disorders. 2021; 51(10):3766-3773.

Harris, K; Lamy, M; Sorter, M; Frye, C; Terhune, L; Erickson, CA; Ruschman, G; Dominick, KC. Letter to the Editor: Chlorpromazine-Induced Skin Pigmentation in a Pediatric Patient. Journal of Child and Adolescent Psychopharmacology. 2021; 31(7):516-517.

Smith, EG; Pedapati, EV; Liu, R; Schmitt, LM; Dominick, KC; Shaffer, RC; Sweeney, JA; Erickson, CA. Sex differences in resting EEG power in Fragile X Syndrome. Journal of Psychiatric Research. 2021; 138:89-95.

Bal, VH; Wilkinson, E; White, LC; Law, JK; Feliciano, P; Chung, WK. Early Pandemic Experiences of Autistic Adults: Predictors of Psychological Distress. Autism Research. 2021; 14(6):1209-1219.

Gillentine, MA; Wang, T; Hoekzema, K; Rosenfeld, J; Liu, P; Guo, H; Kim, CN; De Vries, BBA; Vissers, LELM; Nordenskjold, M; Earl, RK; Nowakowski, T; Bernier, RA; Eichler, EE. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. Genome Medicine. 2021; 13(1):63.

Wink, LK; Reisinger, DL; Horn, P; Shaffer, RC; O'brien, K; Schmitt, L; Dominick, KR; Pedapati, EV; Erickson, CA. Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Journal of Autism and Developmental Disorders. 2021; 51(4):1392-1399.

Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. Using head-mounted eye tracking to examine visual and manual exploration during naturalistic toy play in children with and without autism spectrum disorder. Scientific Reports. 2021; 11(1):3578.

Shillington, A; Lamy, M; Vawter-Lee, M; Erickson, C; Saal, H; Comoletti, D; Abell, K. Case Report: Is Catatonia a Clinical Feature of the Natural Progression of NLGN2-Related Neurodevelopmental Disorder? Journal of Autism and Developmental Disorders. 2021; 51(1):371-376.

Early, M; Doyle, CA; Wink, L; Erickson, CA; Mcdougle, CJ. Clomipramine. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:993-997.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Quetiapine. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:3826-3826.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Serotonin Syndrome. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:4298-4301.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Nortriptyline. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:3196-3196.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Atypical Antipsychotics. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:395-401.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Antidepressant Medications. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:239-243.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Abnormal Involuntary Movement Scale. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:22-22.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Thioridazine. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:4827-4828.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Sertraline. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:4301-4301.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Mesoridazine. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:2878-2878.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Serotonin Reuptake Inhibitors (SRIs) In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:4295-4298.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Aripiprazole. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:310-311.

Early, M; Erickson, CA; Wink, L; Mcdougle, CJ. Chlorpromazine. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:942-943.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Alprazolam. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:145-146.

Early, M; Wink, L; Erickson, CA; Mcdougle, CJ. Thiothixene. In: Encyclopedia of Autism Spectrum Disorders. Springer Nature; 2021:4828-4829.

Schaefer, TL; Ashworth, AA; Tiwari, D; Tomasek, MP; Parkins, EV; White, AR; Snider, A; Davenport, MH; Grainger, LM; Becker, RA; Gibson, JR; Huber, KM; Gross, C; Erickson, CA. GABAA Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome. Frontiers in Psychiatry. 2021; 12:678090.

Schmitt, LM; Dominick, KC; Liu, R; Pedapati, EV; Ethridge, LE; Smith, E; Sweeney, JA; Erickson, CA. Evidence for Three Subgroups of Female FMR1 Premutation Carriers Defined by Distinct Neuropsychiatric Features: A Pilot Study. Frontiers in Integrative Neuroscience. 2021; 15:797546.

Berry-Kravis, E; Filipink, RA; Frye, RE; Golla, S; Morris, SM; Andrews, H; Choo, T-H; Kaufmann, WE. Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort. Frontiers in Pediatrics. 2021; 9:736255.